转移性结直肠癌抗EGFR治疗耐药机制研究进展
Review of research progress on mechanism of resistance to anti-EGFR therapy in metastatic colorectal cancer
徐昆明 1许云华 2陈锡光 1付广 1黄秋林 1肖帅3
作者信息
- 1. 南华大学附属第一医院胃肠外科,湖南衡阳 421001
- 2. 南华大学附属第一医院肿瘤疾病研究所,湖南衡阳 421001
- 3. 南华大学附属第一医院胃肠外科,湖南衡阳 421001;南华大学附属第一医院肿瘤疾病研究所,湖南衡阳 421001
- 折叠
摘要
转移性结直肠癌(mCRC)是结直肠癌进展的晚期阶段,治疗选择多样,但患者预后通常不佳.表皮生长因子受体(EGFR)信号通路在mCRC的发展中扮演核心角色,涉及多个关键分子.EGFR异常活化与肿瘤生长、转移及治疗耐药紧密相关.因此,EGFR靶向治疗对mCRC至关重要,但治疗耐药常常导致治疗失败,且分子机制复杂.在此,笔者综述mCRC抗EGFR治疗耐药的相关分子机制及干预研究进展,为深入理解抗EGFR耐药机制,优化治疗策略提供参考.
Abstract
Metastatic colorectal cancer(mCRC)represents the advanced stage of colorectal cancer progression.Treatment options are diverse,but patient prognosis is generally poor.The epidermal growth factor receptor(EGFR)signaling pathway plays a central role in the development of mCRC,involving multiple key molecules.Abnormal activation of EGFR is closely related to tumor growth,metastasis,and treatment resistance.Therefore,EGFR-targeted therapy is crucial for mCRC,but treatment resistance often leads to therapy failure,and the molecular mechanisms are complex.Here,the authors review the molecular mechanisms related to anti-EGFR treatment resistance in mCRC and the progress in intervention studies,providing a reference for a deeper understanding of the mechanisms of anti-EGFR resistance and the optimization of treatment strategies.
关键词
结直肠肿瘤/肿瘤转移/ErbB受体/分子靶向治疗/抗药性,肿瘤/综述Key words
Colorectal Neoplasms/Neoplasm Metastasis/ErbB Receptors/Molecular Targeted Therapy/Drug Resistance,Neo-plasm/Review引用本文复制引用
基金项目
湖南省自然科学基金资助项目(2022JJ30538)
湖南省自然科学基金资助项目(2023JJ60368)
湖南省卫生健康委员会科研基金资助项目(20201919)
湖南省卫生健康委员会科研基金资助项目(202104010105)
出版年
2024
国家科技期刊平台
NSTL
万方数据